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Abstract Cushing’s disease (CD) is caused by a cortico-
troph, adrenocorticotropic-hormone (ACTH)—secreting
pituitary adenoma resulting in significant morbidity and
mortality. Transsphenoidal surgery is the initial treatment of
choice in almost all cases. Remission rates for microadeno-
mas are good at 65–90 % (with an experienced neurosur-
geon) but remission rates are much lower for
macroadenomas. However, even after postoperative remis-
sion, recurrence rates are high and can be seen up to decades
after an initial diagnosis. Repeat surgery or radiation can be
useful in these cases, although both have clear limitations
with respect to efficacy and/or side effects. Hence, there is a
clear unmet need for an effective medical treatment. Cur-
rently, most drugs act by inhibiting steroidogenesis in the
adrenal glands. Most is known about the effects of keto-
conazole and metyrapone. While effective, access to keto-
conazole and metyrapone is limited in many countries,
experience with long-term use is limited, and side effects can
be significant. Recent studies have suggested a role for a
pituitary-directed therapy with new multireceptor ligand
somatostatin analogs (e.g., pasireotide, recently approved in
Europe for treatment of CD), second-generation dopamine
agonists, or a combination of both. Mifepristone (a gluco-
corticoid receptor antagonist) is another promising drug,
recently approved by the FDA for treatment of hyperglyce-
mia associated with Cushing’s syndrome. We review
available medical treatments for CD with a focus on the two
most recent compounds referenced above. Our aim is to
expand awareness of current research, and the possibilities
afforded by available medical treatments for this mesmer-
izing, but often frightful disease.
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Introduction
Cushing’s disease (CD) is considered an aggressive pituitary
endocrine disorder because of the devastating long-term
consequences of untreated hypercortisolemia. Transsphe-
noidal surgery is clearly the first line therapy of choice; with
remission rates of between 65 and 90 % for microadenomas,
but somewhat lower rates \65 % for macroadenomas [1].
This variability relates to the size and location of tumors,
neurosurgical expertise, length of follow-up, and the defi-
nition of remission. Indeed, this last point is a controversial
aspect in the management of CD, as there is no consensus on
the most accurate postoperative assessment of remission and
its predictive value for long-term prognosis [2]. Further-
more, despite initial cure after surgery, up to a quarter of
patients will experience recurrence within 10 years [3]. Due
to the significance of morbidity and mortality if the disease
is not cured [4], patients require additional effective treat-
ment if initial surgery does fail. A second surgery can be a
desirable choice only in selected cases [5, 6]. Radiotherapy
can also represent an alternative in patients with large
remnant or recurrent disease, but can take several months to
years to reach biochemical normalization and has inherent
adverse effects beyond the risks of panhypopituitarism [7].
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Therefore, there is an urgent need for a medical therapy
that can effectively reverse clinical features of CD by
normalizing CD-associated biochemical parameters
acutely—and more importantly during long-term treat-
ment. Although minimally invasive laparoscopic bilateral
adrenalectomy is an effective and rapid-onset alternative
performed with few short-term complications [8], cortico-
troph adenoma progression is seen in about 30 % of cases,
and may eventually develop to Nelson’s syndrome [9].
Life-long dependence on replacement glucocorticoids and
mineralocorticoids may itself be associated with significant
morbidity due to recurrent adrenal crises.
Until recently, there have been no available medically
licensed treatments, though several compounds had dem-
onstrated efficacy in lowering excess cortisol in selected
CD cases [7]. The most physiological approach targets
ACTH secretion at the level of the pituitary, with possible
inhibition of corticotrope proliferation (Fig. 1, [10]). Pa-
sireotide, a new multiligand somatostatin analog has
recently been studied in this regard. Another recent treat-
ment target has been the glucocorticoid receptor. Drugs
frequently used now in clinical practice are steroidogenesis
inhibitors, which reduce cortisol levels in the adrenal
glands. More recently, combination therapy has been also
tried with drugs from similar or different groups [11, 12].
Interpretation of available data on the efficacy and
safety of most drugs currently used in the treatment of CD
is difficult. A review of published reports indicates that
study design has varied considerably with a few small
prospective, controlled, randomized studies available.
Furthermore, it is unclear whether some of those studies
could potentially represent publication bias. There is also
significant variation in biochemical parameters used for the
primary endpoint (e.g., urine free cortisol [UFC], serum
and salivary cortisol, and plasma ACTH) and, with few
exceptions [13, 14], reference values derived from a suf-
ficiently large population are largely lacking, especially for
some of the more recently developed assays. Unfortu-
nately, the criteria for defining a clear and effective
response to treatment, and for disease control, are insuffi-
cient [1].
Pituitary-targeted therapy
The aim of pituitary-targeted therapy is to directly act on
the underlying pituitary tumor/ACTH hypersecretion
source. Although, for many years, various drugs have been
tried with limited efficacy, recent approaches may even-
tually allow for medical treatment of selected patients with
CD. Currently, three classes of drugs are under investiga-
tion in humans: (1) somatostatin analogs, (2) dopamine
agonists, and (3) PPARc ligands.
Somatostatin analogs
Table 1 [10] summarizes several studies investigating the
expression of the 5 somatostatin receptor subtypes in cor-
ticotropic pituitary adenomas [15–21]. Although sst1, sst2,
and sst5 are widely expressed, the expression levels are
low, except for sst5 [18]. Interestingly, however, both sst2
Fig. 1 Current approaches to medical therapy in CD, with com-
pounds listed aside their main level of action. Ref. [10] (adapted from
Petersenn S, Endocrine Updates, 2011 with kind permission from
Springer Science?Business Media B.V.)
Table 1 Expression of somatostatin receptors in corticotropic pituitary adenomas
Reference Method sst1 sst2 sst3 sst4 sst5
Greenman [16, 17] RPA, RT-PCR 1/3 0/3 1/2 0/1 1/1
Miller [19] RT-PCR 3/5 5/5 0/5 0/5 4/5
Nielsen [20] RT-PCR 0/1 0/1 1/1 1/1 0/1
Panetta [21] RT-PCR 1/1 1/1 1/1 0/1 0/1
Batista [15] Realtime RT-PCR 12/13 (high) 9/13 (low) 0/13 (-) 5/13 (?) 13/13 (high)
Hofland [18] Realtime RT-PCR 1/6 (low) 6/6 (low) 2/6 (low) 2/6 (low) 6/6 (high)
Author’s data (SP) Realtime RT-PCR 7/10 (low–high) 8/10 (low–high) 3/10 (med) 4/10 (high) 7/10 (low–high)
Total (%) 25/39 (64 %) 29/39 (74 %) 8/38 (21 %) 12/37 (32 %) 31/37 (84 %)
Ref. [10] (adapted from Petersenn S, Endocrine Updates, 2011 with kind permission from Springer Science?Business Media B.V.)
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ligands and sst5 ligands were found to inhibit corticotropin-
releasing hormone (CRH)-stimulated ACTH secretion in
vitro in a mouse corticotropic cell model [22]. Stalla et al.
demonstrated clear efficacy of the sst2 ligand octreotide in
primary cell culture of corticotropic pituitary tumors [23].
This effect, however, was abolished by pretreatment with
glucocorticoids, which may be explained by downregulation
of sst2 by glucocorticoids. A study of a transient transfection
system suggested a negative glucocorticoid responsive ele-
ment in the sst2 promoter [24], indicating transcriptional
inhibition of sst2 by glucocorticoids. Assuming inhibition of
sst2 expression in the corticotropic pituitary tumor by con-
tinuously elevated systemic cortisol levels, sst2 ligands
would be largely ineffective in vivo. Indeed, although the
clinical experience is limited, single injections of octreotide
100 lg did not demonstrate any effect on ACTH levels in
several studies of patients with hypercortisolism [23, 25, 26].
Furthermore, short-term treatment of patients with CD with
repeated subcutaneous injections of octreotide proved to be
largely ineffective [27, 28].
An alternative approach may be to use sst5 ligands,
considering the high expression of sst5 in corticotropic
adenomas. Pasireotide (SOM230) is a recently developed
multi-receptor ligand somatostatin analog. Whereas octreo-
tide and lanreotide have high affinity for sst2 and modest
affinity for sst5, pasireotide demonstrates high binding
affinity for sst1,2,3 and sst5, and has a 40-fold higher affinity
for sst5 than octreotide (Fig. 2, [10, 29, 30]). Pasireotide was
highly effective in lowering ACTH secretion in a mouse cell
model. Of note, dexamethasone pre-treatment did not
influence the sensitivity of the cells to the inhibitory effect of
pasireotide, suggesting that sst5 is relatively resistant to
negative control by glucocorticoids [18]. Indeed, quantita-
tive PCR analysis showed that sst5 mRNA levels were not
significantly affected by dexamethasone treatment, whereas
dexamethasone lowered sst2 mRNA expression significantly
[31]. In primary cultures of corticotropic pituitary adenomas,
pasireotide inhibited ACTH secretion in 3/5 [18] and 5/6
[15] tumors, respectively. In addition, significant suppres-
sion of cell proliferation was observed in all tumors cultured
in the later study. The strong inhibition of the hypothalamic–
pituitary–adrenal (HPA) axis by pasireotide was confirmed
in an animal model. Pasireotide suppressed both CRH-
induced ACTH release and corticosterone secretion in rats
[32]. By overexpression of either sst2 or sst5 in a mouse cell
model, it was clearly shown that the suppressive effects of
pasireotide in corticotropic cells are determined by sst5,
whereas the ligand action on sst2 is negligible [33]. In a
phase II, proof-of-concept, open-label, single-arm, multi-
center study, the in vivo efficacy of pasireotide was evalu-
ated in patients with either de novo CD, or with persistent or
recurrent CD [34]. A total of 39 patients were recruited from
ten centers in five countries. Approximately 44 and 21 % of
patients had a history of a micro- or macroadenoma,
respectively, with no visible adenoma or unknown adenoma
status in the remaining patients. Baseline UFC levels ranged
from 291 to 5,950 nmol/24 h, with a mean of 1,231 nmol/
24 h—approximately 4.5 times the upper limit of normal.
Thirty-eight patients completed the study, while one patient
with a preexisting history of diabetes mellitus discontinued
treatment because of grade 2 hyperglycemia. Data from 29
patients were available for the primary efficacy analysis.
Five patients had fewer than two UFC sample determina-
tions at baseline or study end, and four patients fulfilled
inclusion criteria but had a baseline mean UFC level within
the normal range of the central laboratory assay in contrast
to increased UFC levels in the local assay. Patients self-
administered pasireotide 600 lg subcutaneously twice daily
for 15 days, at 0900 and 2100 hours. After the treatment
period of 15 days, the mean UFC level decreased signifi-
cantly by 44.5 %. The mean UFC level significantly
decreased from 1,231 nmol/24 h at baseline, to 683 nmol/
24 h at study end. Normalization of UFC was found in 17 %
(5/29) of patients, with 76 % (22/29) of patients demon-
strating a reduction in UFC levels. Although a significant
correlation between baseline UFC level and UFC level at
day 15 was not observed, there was a trend towards a lower
baseline UFC level reported as being predictive of a
response to pasireotide. Pharmacokinetic data for pasireotide
showed an approximately 1.8-fold higher trough plasma
concentration and a 1.3-fold higher plasma exposure in UFC
responders than nonresponders. Therefore, the clinical
response may be related to pasireotide plasma exposure,
requiring pasireotide trough level or plasma exposure above
a certain threshold for an optimal clinical response. Steady-
state levels of pasireotide were achieved within five days of
treatment initiation. Reported side effects with a frequency
Fig. 2 Preferential affinities of somatostatin, somatostatin analogs
octreotide and lanreotide, and the new multi-receptor ligand somato-
statin analog pasireotide for the five known somatostatin receptor
subtypes sst1–sst5. Ref. [10] (adapted from Petersenn S, Endocrine
Updates, 2011 with kind permission from Springer Science?Business
Media B.V.)
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of at least 10 % included GI-related conditions (diarrhea
[44 %], nausea [23 %], abdominal pain [18 %]), asthenia
(13 %) and fatigue (10 %), hyperglycemia (36 %), head-
ache (18 %), as well as hypotension (13 %). These very
much resemble the side effects observed with currently
licensed somatostatin analogs. Hyperglycemia was reported
in 36 % (14/39) of patients, and appeared to be more notable
in patients with a history of impaired fasting blood glucose
or diabetes mellitus.
More recently, the results of a phase III, randomized,
double-blind, multicenter trial on pasireotide in CD were
published [35]. In that study, 162 patients with persistent or
recurrent, or de novo CD ineligible for surgery were ran-
domized to receive pasireotide 600 lg or 900 lg subcu-
taneously bid for 12 months. Hypercortisolism had to be
confirmed with a mean baseline UFC (based on four col-
lections) C1.59 the upper limit of normal. Key exclusion
criteria included pituitary irradiation within the last
10 years, compression of the optic chiasm, and poorly
controlled diabetes mellitus. At three months, patients with
a mean UFC[29 the upper limit of normal or higher than
baseline were unblinded and the dose increased by 300 lg.
The primary endpoint was the proportion of patients at
six months achieving normalization of UFC without dose
up-titration at month 3 relative to the randomized dose. The
authors reported that 15 and 26 % for the 600 and 900 lg
doses, respectively, met the primary endpoint (Fig. 3,
[35]). The lower normalization rate in the 600 lg bid dose
group was considered to be due to the higher baseline mean
UFC in that group (1,156 vs. 782 nmol/24 h in the 900 lg
bid group). Both groups included mainly patients with
severe disease. There was a clear reduction in median UFC
at 12 months of -67.6 % (600 lg) and -62.4 % (900 lg).
Interestingly, lack of response could be identified within
2 months in the vast majority of patients. Serum and sali-
vary cortisol, and plasma ACTH decreased in both groups.
As UFC levels decreased, clinical improvements (e.g., with
respect to blood pressure, body weight, health-related
quality of life) were evident at month 6 and month 12
(Fig. 4, [35]). The most frequently reported adverse events
were diarrhea (58 %), nausea (52 %), hyperglycemia
(40 %), and cholelithiasis (30 %); most were Grade 1/2.
Fasting plasma glucose and HbA1C levels were increased
during treatment with pasireotide, and 73 % of patients had
a hyperglycemia-related adverse event. The mean HbA1C
increased from 5.8 % in both the 600 and 900 lg groups at
baseline to 7.2 and 7.4 %, respectively, at month 6.
Therefore, patients require careful monitoring of their
glucose levels. Following on these results, the European
Medicines Agency approved pasireotide in April 2012 for
the treatment of adult patients with CD for whom surgery is
not an option or for whom surgery has failed [36].
In a recent case report, a dramatic drop of elevated UFC
levels in a patient treated with pasireotide 600 lg bid was
observed, leading to symptomatic and biochemical hypo-
cortisolism [37]. Prior to pasireotide, the patient demon-
strated UFC levels approximately 1.5-2-fold above normal,
despite three surgical attempts and radiotherapy. After
10 months of reduced pasireotide therapy (300 lg bid) the
patient continued to demonstrate improved mood, stable
weight and normal UFC levels. Bode et al. [38] reported a
female patient with a giant adenoma that was initially
treated by transcranial resection. Due to a symptomatic
relapse and tumor recurrence, the patient received stereo-
tactic radiosurgery, followed by bilateral adrenalectomy.
Subsequently, the patient was diagnosed with a pituitary
carcinoma due to the development of several intracranial
and spinal metastases. She was started on temozolomide,
with another dramatic rise in ACTH levels (from 882 to
3,868 ng/mL) early after initiation of therapy. As a salvage
therapy, she received pasireotide 900 lg subcutaneously
bid. ACTH levels decreased to 1,738 ng/mL after 2 weeks.
ACTH levels than remained at 900–1,000 ng/mL, and her
clinical status improved. The combination of temozolo-
mide and pasireotide led to sustained tumor control for
12 months, after which temozolomide was stopped. The
Fig. 3 Absolute change of UFC
from baseline to month 6 in 103
patients treated with pasireotide.
Black dashed line represents
ULN. Ref. [34]. Reproduced
with kind permission from the
Massachusetts Medical Society
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patient then remained stable on monotherapy with pasire-
otide for more than nine months. The authors themselves
state that they cannot dissect the efficacy of both therapies.
However, the combination of temozolomide and pasireo-
tide may be a promising option for the treatment of ACTH-
secreting pituitary carcinomas.
Dopamine agonists
Dopamine subtype 2 receptors are expressed in cortico-
troph pituitary adenomas [39]. Bromocriptine has been
shown to inhibit ACTH secretion [40] and apoptosis in an
ACTH-secreting mouse cell line [41]. In a combined
review of 23 patients with CD treated with 1.25–30 mg/day
of bromocriptine for 3–180 weeks, a response rate of 48 %
[42] was observed. Of note, primary endpoints for indi-
vidual studies have varied (e.g., plasma cortisol levels,
cortisol secretion rates, and 24-h urinary glucocorticoid
assessments). Subsequent series have demonstrated sig-
nificantly lower response rates (4–23 %) [43, 44]. Newer
dopamine agonists may be more effective. In a single-
center study of ten patients treated with cabergoline
(1–3 mg/week for 3 months), a normalization rate of 40 %
for UFC was observed [45]. Moreover, the same authors
confirmed the long-term efficacy of cabergoline in CD in a
subsequent study, in which normalized UFC was main-
tained in 40 % of 20 patients for at least 12 months of
follow-up [46]. A dose of 1–7 mg/week (median 3.5 mg)
was well tolerated, except by two patients with hypotension
and severe asthenia, who stopped treatment after 12 and
18 months, respectively. This data was recently confirmed
by Godbout et al. [47], who treated 30 CD patients with
cabergoline, up to 6 mg/week. Thirty percent of patients
demonstrated long-term normalization of UFC for
12–60 months, with a mean dose of 2.1 mg/week. Whether
or not recently documented cardiac valve changes in
patients with Parkinson’s disease receiving much high
doses of cabergoline [48, 49] equate to the lower doses
applied in this cohort is not clear. Of note, Pivonello et al.
[46] documented no development of cardiac valve insuf-
ficiency and one case of worsening of a previously diag-
nosed tricuspid regurgitation. The results of this single-
center experience need to be confirmed in a larger multi-
center study that examines both efficacy and safety.
PPARc (peroxisome proliferator-activated receptor-
gamma)
PPARc (peroxisome proliferator-activated receptor-gamma)
is a member of the nuclear receptor superfamily, and func-
tions as a transcription factor. PPARc ligands have been
shown to inhibit the growth of many tumors, including breast,
colon, and prostate cancer cells [50]. Furthermore, PPARc
ligands have demonstrated antiproliferative and apoptotic
effects in a murine cell model of corticotropic adenoma cells,
and inhibited proopiomelanocortin (POMC) transcription
[51]. However, very little PPARc protein was found in pitu-
itary adenomas. Additionally, the antiproliferative effects of
Fig. 4 Change from baseline to month 12 in systolic blood pressure,
diastolic blood pressure, body weight, and health-related quality of
life (HRQoL) (measured using CushingQoL questionnaire, scored
from 0 to 100, with higher scores indicated better QoL) among
patients treated with pasireotide. Bars indicate SEM. Ref. [34]
(adapted from Colao A, et al. N Engl J Med 2012). Reproduced with
kind permission from the Massachusetts Medical Society
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PPARc ligands were only observed with very high doses of
rosiglitazone, without significant reversal by a PPARc
antagonist [52]. In CD, suppression of steroidogenesis in the
adrenal glands via inhibition of P450c17 and 3ßHSD could
also be beneficial [53], however clinical experience is limited
so far. In a study of rosiglitazone (8–16 mg) in 14 patients
treated for 1–7 months, normalization of UFC was observed
in 42.9 % of patients, with mild improvement in clinical
features [54]. A subsequent study in ten patients treated for
1–8 months with 4–16 mg rosiglitazone demonstrated nor-
malization of UFC in 30 % of patients [55]. Side effects,
however, were significant and included edema, hypertension,
weight gain, somnolence, increased hirsutism, and bruis-
ability. Thus, patients were unwilling to re-enter the treatment
protocol [55]. Morcos et al. [56], in a report on long-term
treatment of central Cushing’s syndrome with rosiglitazone
observed an initial decrease in ACTH, but with a rebound
after 28 weeks of therapy, despite dose increases of up to
28 mg. Suri and Weiss published a report on the effect of
pioglitazone on ACTH and cortisol secretion in CD. They
showed that pioglitazone at 45 mg for one month had no
noteworthy effects on either ACTH or cortisol secretion. This
study was, however, undertaken in a small study cohort [57].
At a consensus conference, in the investigator panel’s expert
opinion, it was concluded that current study results did not
sufficiently supported routine clinical use of PPARc ligands
to treat CD [1]. Additionally, there are concerns related to
PPARc ligands and increased cardiovascular disease risks
[58], which means that PPARc ligands are not the ideal drug
of choice for patients with Cushing’s who are already at high
risk of heart problems.
Glucocorticoid receptor antagonist therapy
Use of a glucocorticoid receptor blocker represents another
medical therapy approach to treat CD [59]. Hypercorti-
solemia persists, but the devastating effects are ameliorated
by the antagonist binding to the glucocorticoid receptor—a
concept that is similar to the use of pegvisomant when
treating acromegaly [60]. Mifepristone is currently the only
available glucocorticoid receptor antagonist [61–63]. Mi-
fepristone directly blocks the cortisol glucocorticoid
receptor (GR-II) and the progesterone receptor (PR). There
are 51 published case reports detailing the use of mifepri-
stone in treating hypercortisolism (five in CD patients) [64,
65]. Chu et al. [66] presented a case report on a patient with
an ACTH-secreting pituitary macroadenoma who had
failed multiple therapies and was too ill to undergo bilat-
eral adrenalectomy. A dramatic improvement in clinical
symptoms was reported with mifepristone (starting dose
6 mg/kg/day, up to a maximum of 25 mg/kg/day) over
18 months. Severe hypokalemia (which was responsive to
spironolactone administration) was attributed to excessive
cortisol activation by the mineralocorticoid receptor. In a
retrospective report (from seven European centers) on the
use of mifepristone in patients with hypercortisolism, four
additional patients with CD were presented [65]. Clinical
symptoms improved in three during treatment over
3–24 months. The fourth patient was treated for
0.5 months, during which rapid improvements in psychi-
atric symptoms were demonstrated. The patient later
underwent surgery. Severe hypertension and hypokalemia
developed in one patient.
The multi-center, open-label, six-month United States
SEISMIC study included 50 subjects (43 with CD) [67].
Subjects with confirmed endogenous Cushing’s syndrome
were placed in two groups, based on the presence of addi-
tional eligibility criteria: type 2 diabetes mellitus or
impaired glucose tolerance (C-DM cohort), or hypertension
(C-HT cohort). Doses of daily mifepristone ranged from
300 to 1,200 mg, with a mean of 900 mg. Overall, 60 % of
the 29 patients with glucose intolerance or diabetes
(p \ 0.0001) were defined as responders (a C 25 %
reduction in glucose on a standard oral glucose tolerance
test as measured from baseline to 24 weeks). There was a
continued improvement in glucose tolerance measured at
each of the evaluations at weeks 6, 10, 16, and 24 (Fig. 5
[67]). Of the 12 patients taking insulin at baseline, seven
were able to cut their daily dose by C50 %. There was also a
statistically significant reduction in mean HbA1c over the
course of the study, from 7.43 % at baseline to 6.29 % at
study conclusion (p \ 0.001). Of the 21 patients enrolled in
the hypertension group, 38 % (p \ 0.05) achieved a 5 mm
reduction in diastolic blood pressure. Increases or additions
of antihypertensive medications were not permitted with the
exception of mineralocorticoid receptor antagonists.
Among the 40 patients with hypertension (from both
groups), 42.5 % had a reduction in diastolic blood pressure
C5 mmHg. Fifty-two percent had either a decrease in dia-
stolic blood pressure or a reduction in antihypertensive
medications at week 24. Over half of the patients experi-
enced weight loss of C5 % when compared to baseline
(p \ 0.001). Mean percent total body fat declined by 3.6 %
by week 24 (p \ 0.001) (Fig. 6 [67]). Eighty-seven percent
of patients receiving mifepristone in the study experienced
improvement in their individual clinical manifestations
(assessed by eight clinical parameters by a blinded data
review board). Elevation in cortisol (up to sevenfold) and
ACTH (up to twofold) was observed in all patients with CD,
and returned to baseline after stopping drug. There were two
cases of adrenal insufficiency (AI), although symptoms
compatible with AI (e.g., weakness, nausea, fatigue,
abdominal pain, emesis, hypotension) were more frequent.
Use of glucocorticoid rescue was limited to six patients.
Hypokalemia (as expected) was common but generally mild
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to moderate and associated with alkalosis and edema. There
were three cases of severe hypokalemia (defined as
K B 2.5 mmol/L) during treatment. All cases responded
well to potassium replacement and spironolactone, albeit at
significantly high doses. Given that mifepristone has anti-
progestin effects, endometrial effects were expected. An
increase in endometrial thickness was observed in 38% of
the females in the study. There were five cases of vaginal
bleeding, two with prolonged bleeding even after stopping
drug, and three women underwent subsequent dilatation and
curettage (D&C) for non-resolved endometrial thickening
after stopping mifepristone. Overall, for most study
patients, this drug had an acceptable benefit-risk profile.
The lack of a biochemical marker correlating with the
treatment response dictates that efficacy measurements
should be based on symptoms, clinical features, and met-
abolic improvements. Of note, direct translation of clinical
study data to day-to-day use in a busy clinical practice can
be challenging. Monitoring side effects like hypokalemia
and hypertension, as well as early recognition of clinical
AI, is essential. Long-term effects of mifepristone on tumor
size and endometrial effects are as yet undetermined, and
further long-term studies are ongoing [68]. The develop-
ment of a selective glucocorticoid receptor without anti-
progestin effects [69] could also represent an important
step in the long-term treatment of women with CD.
Fig. 5 Mean change from baseline to week 24/ET in glycemic
parameters (AUCglucose and plasma and fasting plasma glucose as
measured by 2-h OGTT, and HbA1c) among patients treated with
mifepristone. Bars indicate SD (AUC, area under the curve; C-DM,
Cushing’s with diabetes mellitus or hyperglycemia; OGTT, oral
glucose tolerance test; ET, early termination) [67] (adapted from
Fleseriu M, et al. J Clin Endocrinol Metab 2012. Copyright 2012, The
Endocrine Society)
Fig. 6 Mean change from baseline to week 24/ET in body weight
and composition among patients treated with mifepristone. Bars
indicate SEM [67] (mITT, modified intent to treat) (adapted from
Fleseriu M, et al. J Clin Endocrinol Metab 2012. Copyright 2012, The
Endocrine Society)
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Adrenal-directed therapy: steroidogenesis inhibitors
Steroidogenic drugs have been particularly useful in
treating patients with severe hypercortisolism who are
waiting for surgery, after noncurative surgery, or as bridge
until radiation therapy becomes effective.
The principle of steroidogenesis inhibition originated
60 years ago with studies on amphenone B [70, 71]. To date,
most is known about the effects of metyrapone, ketocona-
zole, and mitotane, which are reportedly more effective and
better tolerated, but other drugs have been studied (Table 2).
A combination of these drugs may have an additive or
synergistic effect, potentially allowing for smaller doses.
Treatment monitoring is necessary for hypocortisolemia and
any other adverse effects. An approach sometimes used is to
totally block adrenal steroidogenesis and add physiologic
glucocorticoid replacement [72].
Metyrapone
Metyrapone was studied in humans soon after the discovery
of its steroidogenesis blocking effects in animals [73]. It has
been used as monotherapy or in combination. Metyrapone
mainly acts via inhibition of 11-b-hydroxylase and to a
lesser extent 17-a-, 18-, and 19-hydroxylase activities [74]
and therefore, aldosterone biosynthesis is more severely
affected than that of cortisol [75]. Initial doses are usually
250 mg qid, which can be adjusted during treatment to a
total daily dose of 500–6,000 mg [1]. In patients with CD, a
significant drop of cortisol levels is observed 2 h after a first
dose [76]. Short-term metyrapone therapy induces clinical
improvements in the majority of patients, with biochemical
control in 75 % (median dose of 2,250 mg/day; range
750–6,000 mg/day). Long-term use (median 27 months,
range 3–140 months) induced even higher rates of bio-
chemical remission (83 %), most likely due to an additive
effect of pituitary irradiation. Jeffcoate et al. [77], reported
biochemical control of 13 patients with CD for up to
66 months with metyrapone (nine had received pituitary
irradiation in addition to metyrapone. ACTH secretion may
override steroidogenic blockade in some patients with CD
[39]. However, as reported in one of the largest studies on
metyrapone, this effect predominantly occurred in the first
4–6 weeks following initiation of therapy, after which no
further increase was observed [76].
Adrenal insufficiency has been observed in 13 % of patients
[76]. Acne and hirsutism (19–70 %) due to increased andro-
gens are relatively frequent, though mostly mild in nature [77],
thus making metyrapone a clear second choice in women. As a
result of increased 11-deoxycorticosterone levels, hypokale-
mia (6 %), edema (8 %) and hypertension are also observed
[76]. Other rare adverse effects included cutaneous rash (4 %),
which may be transient, effects on the central nervous system
(e.g., lethargy and dizziness, 15 %), and gastrointestinal
complaints (e.g., nausea, 5 %). Metyrapone has limited
availability in many countries (e.g., Germany, United States),
but can be ordered through an international drugstore or by
contacting the manufacturer (Novartis) directly.
Ketoconazole
Ketoconazole, initially licensed as an antifungal agent, was
observed to lower cortisol [78] and testosterone [79] levels
via inhibition of a variety of cytochrome P450 enzymes
(side-chain cleavage complex, 17,20-lyase, 11-b-hydroxy-
lase, and 17-a-hydroxylase) [80, 81]. Inhibition of ACTH
secretion or action as a glucocorticoid receptor antagonist
have been described in cell models, but there is a lack of
clear evidence in humans [1, 42]. Ketoconazole treatment is
usually started at 200 mg bid [1], and biochemical effect
achieved at 600–800 mg/24 h [42]. A meta-analysis of 12
studies treating 85 CD patients reported 81 % normalization
of urinary steroids [42]. A recent retrospective analysis
found normalization of UFC in 45 % of patients (mean
follow-up of 23 months; range 6–72 months) [82]. Escape
from pharmacological control has been reported [83]. Rapid
improvement in clinical symptoms, and regression of dia-
betes mellitus, hypokalemia, hypertension, hirsutism, and
depression have been reported [75]. Ketoconazole may
reduce cholesterol [84] and vitamin D levels [85]. Side
effects are, in general, dose-dependent and include:
gynecomastia (13 % of males), gastrointestinal symptoms
(8 %), edema (6 %), and skin rash (2 %) [39]. Ketoconazole
represents a second-line in men due to the possible devel-
opment of hypogonadism. Liver function should be moni-
tored carefully, but mild and transient elevations in liver
enzymes of up to threefold of normal are not a contraindi-
cation for further treatment. Typically, onset of ketocona-
zole-induced hepatitis is reported to occur within 60 days
after initiation of treatment and resolves within 3 months of
discontinuation [86]. More severe abnormalities such as
severe hepatic injury (seen in 1/15,000 cases) [87] require
discontinuation [1].
Table 2 Adrenal steroidogenesis inhibitors
Drug Initial dose Maximal
dose in CD
Ketoconazole 200 mg bid 400 mg tid
Metyrapone 250 mg qd 1,500 mg qid
Mitotane 500 mg tid 1,000 mg tid
Etomidate Bolus of 0.03 lg/kg iv, followed by
infusion 0.1 mg/kg/h
0.3 mg/kg/h
Mitotane doses may need to be reduced after 3 months due to satu-
ration of fat tissue and subsequent overspill, look for minimal effi-
cious dose and avoid drug levels [20 lg/mL
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The availability of ketoconazole is also limited in many
countries. However, fluconazole appears to have similar
effects [88], with normalized UFC levels (in the author’s
[SP] limited experience with two patients treated with
fluconazole 100 mg bid).
Mitotane (o,p0-DDD)
Mitotane inhibits steroidogenesis at the steps of side chain
cleavage, 11- and 18-hydroxylase and 3-b-hydroxysteroid
dehydrogenase. Its main use is in treatment of adrenocor-
tical carcinoma, but has been proven effective in CD [89].
In a study of 46 patients treated for 3–34 months at doses
of 8–12 g/24 h (different formulation than currently
available preparations, which require lower doses), 83 %
achieved normalization of urinary markers [90]. Sixty
percent of patients relapsed after withdrawal of therapy,
suggesting adrenolytic action is limited [90, 91]. Action is
slow and saturation can be expected 2–3 months after
initiation of therapy. Due to an accelerated metabolism of
exogenous steroids, especially hydrocortisone, replacement
doses must be increased to avoid adrenal crises [92, 93]. In
contrast to its use in adrenal carcinoma, specific target
ranges for drug concentrations in CD have not been
established. Significant and frequent side effects include
disturbances of the gastrointestinal tract (72 %) and the
central nervous system (impaired mentation and dizziness,
45 %), as well as gynecomastia, rash, increases in liver
enzymes, and hypercholesterolemia [42]. Therefore, its use
should be limited to centers with special experience.
Recently, a defined preparation was licensed in Europe
(Lysodren, Bristol-Myers Squibb).
Aminoglutethimide
Aminoglutethimide inhibits the side-chain cleavage of
cortisol biosynthesis and a variety of steroidogenic
enzymes, e.g. side-chain cleavage complex, 21-hydroxy-
lase, 17-a-hydroxylase, 11-b-hydroxylase, aromatase,
17–20 lyase, and 18-hydroxylase [42, 75]. Aminoglutethi-
mide appears to be somehow more effective in patients
with autonomous adrenal hyperfunction or ectopic ACTH
production compared to patients with CD, possibly due to
ACTH stimulation overriding the adrenal blockade in the
latter group. As of this writing, the compound has only
limited availability worldwide.
Etomidate
The non-opioid anesthetic etomidate induces adrenocorti-
cal suppression by dose-dependent inhibition of 11-b-
hydroxylase and desmolase. It is the only such compound
available for intravenous administration, thus being useful
in situations where rapid control of hypercortisolism is
required, or oral therapy is contraindicated. An initial bolus
of 0.03 mg/kg is followed by an infusion of 0.03–0.3 mg/
kg/h. Significant suppression of serum cortisol levels is
observed quickly (after *5 h), with a maximum effect at
*11 h [94–96].
LCI699
LCI 699 is a potent inhibitor of 11-b-hydroxylase and
18-hydroxylase (aldosterone synthase) [97, 98] currently
under investigation in a proof-of-concept study in patients
with CD. Preliminary results [99] from 10 weeks treatment
in 12 patients with mild to severe CD (UFC [ 1.5xULN)
showed UFC normalization in 11/12 patients, and all patients
achieved the study’s primary endpoint (UFC B ULN or
C50 % reduction in UFC from baseline). Median LCI699
dose associated with UFC normalization was between 5 and
10 mg bid. LCI699 was generally well tolerated, and no
serious drug-related adverse events were reported. The most
common adverse events were fatigue (7/12), nausea (5/12)
and headache (3/12). Four patients experienced study-drug–
related hypokalemia (K? \ 3.5 mmol/L; min 3.1 mmol/L).
Based on these promising results, evaluation of LCI699 in
patients with CD is ongoing.
Combination therapy
Interaction between somatostatin analogs and dopamine
receptor agonists may allow for synergistic suppression of
ACTH. Feelders et al. [11] studied 17 patients with pa-
sireotide alone or with cabergoline and ketoconazole in CD
(mean age, 45.7 years; 13 women) in an 80-day trial with
normalization of urinary free cortisol (UFC) levels as the
main outcome measure. Pasireotide monotherapy induced
sustained normalization of UFC levels in five patients, and
addition of cabergoline succeeded in normalizing an
additional four patients. Despite a C 50 % decrease in
UFC, 8/17 patients (47 %) still had elevated UFC levels
after two months on the combined treatment. The addition
of low-dose ketoconazole increased the number of patients
with a complete response to 88 % after a further
two months.
Another study reported on the effectiveness of caberg-
oline (at doses of up 3 mg/week) combined with relatively
low doses of ketoconazole (up to 400 mg/day) in patients
with CD who were unsuccessfully treated by transsphe-
noidal surgery [100]. Whereas treatment with cabergoline
alone for six months allowed normalization of UFC in
3/12 patients, the addition of ketoconazole to the nine
patients with insufficient response normalized UFC in an
additional six patients.
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Combination therapy with mitotane (3–5 g/24 h),
metyrapone (3–4.5 g/24 h) and ketoconazole (400–1,200
mg/24 h) as an alternative to urgent adrenalectomy has
been recently reported in 11 patients with severe CD [12].
In all patients, high doses of these drugs were simulta-
neously started, and UFC decreased within 24–48 h. After
this treatment, five patients were able to undergo surgery
directed at ACTH excess. Side effects were tolerable and,
interestingly, no greater than would be expected for each
medication alone.
Conclusions
Cushing’s disease is a debilitating condition, with increased
morbidity and mortality if biochemical remission/cure not
achieved. Transsphenoidal surgery is the first-line treatment
of choice, but does not result in a cure for many patients.
Medical therapy represents a potentially useful addition to
the range of available treatment options for many patients
with CD for whom surgery has failed or is not possible.
While adrenal steroidogenesis inhibitors are clearly effec-
tive, there have been few controlled trials, and little experi-
ence with their long-term use. Clinically important side
effects have also limited the therapeutic potential of avail-
able therapies, and there is a possibility of publication bias
for this class of therapies. Further, drugs of this type do not
target the underlying pituitary tumor, and escape of ACTH
secretion may require dose adjustments to maintain efficacy.
Pituitary-targeted therapies may provide both an anti-
secretory and an anti-proliferative treatment. Dopamine
agonists have demonstrated some efficacy in small proof-of
concept studies. A new somatostatin receptor ligand, pa-
sireotide, has shown clear biochemical and clinical response.
Similarly, treatment with the glucocorticoid receptor
antagonist, mifepristone demonstrated clinical improve-
ment. Our present knowledge of combination therapy is
limited to case reports and a few small proof-of-concept
studies; current data indicate, however, that a multimodal
pharmacologic treatment approach may offer additive or
synergistic clinical benefit with acceptable tolerability.
Medical therapy for CD poses unique challenges and, unlike
the biochemical control and tumor shrinkage achieved in
patients with prolactinomas and acromegaly, comparable
results have not yet been achieved in patients with CD.
However, research is progressing rapidly, and we are getting
closer to a more ideal treatment for this implacable disease.
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